For example, in an orthotopic model of recurrent GBM, we showed that MDM2 inhibition decreased the resistance to the standard-of-care agent temozolomide by sustaining p53 activation and blocking DNA repair [92]. This evidence concerns the gene MDM2 and glioblastoma.